Page 2 - Win Ratio News Today

Ahmad Masri, MD, MS, discusses new acoramidis data from the ATTRibute-CM trial at AHA 2023.

- As previously announced, the primary endpoint was met with a highly statistically significant p-value - The placebo and acoramidis time-to-first event Kaplan-Meier curves for a composite of...

- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related...

- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant

On the floor at HFSA 2023, Muthiah Vaduganathan, MD, MPH, provides his perspective on the latest IV iron supplementation guidelines from the European Society of Cardiology.

The largest trial to date, a meta-analysis, and new guideline recommendations have placed a spotlight on the role and benefit of iron supplementation in patients with heart failure and iron deficiency at ESC Congress 2023.

- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently...

With BridgeBio Pharma Inc. expecting to complete a regulatory submission prior to the close of 2023, the 30-month results of ATTRibute-CM provide the most comprehensive overview yet of the benefit-risk profile for acoramidis in ATTR-CM.

BridgeBio Pharma Inc (NASDAQ: BBIO) released results from ATTRibute-CM Phase 3 study of acoramidis in transthyretin 

Announced on July 17, 30-month data from the ATTRibute-CM trial provide the most comprehensive insight yet into the long-term effects of acoramidis use in patients with transthyretin amyloid cardiomyopathy.